| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC12714 | CLP-290 Featured | CLP290 (CLP-290) is an orally acirtve small molecule K+-Cl- cotransporter isotype 2 (KCC2) activator, the carbamate prodrug of CLP257; In vivo co-treatment with morphine and oral CLP290 prevented membrane KCC2 downregulation in SDH neurons. Concurrently, co-treatment with CLP290 significantly mitigated MIH and acute administration of CLP257 in established MIH restored normal nociceptive behavior. |
|
| DC11061 | ClpP inhibitor M21 | ClpP inhibitor M21 is a noncompetitive inhibitor of ClpP with IC50 of 41.42 uM, inhibits ClpP cleavage of SUc-LY-AMC substrate in a peptidase assay. |
|
| DC11067 | CLSP37 | CLSP37 (RIPK2 inhibitor CLSP37) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 16.3 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC11068 | CLSP43 | CLSP43 (RIPK2 inhibitor CLSP43) is a novel potent, ATP pocket-binding RIPK2 inhibitor with IC50 of 19.9 nM in ADPGlo assay, demonstrates inhibition of both the RIPK2-XIAP interaction, and of cellular and in vivo NOD2 signaling. |
|
| DC21063 | CM03 | CM03 is a G-quadruplex-binding compound that potently inhibits cell growth in PDAC cell lines (MIA PaCa-2 IC50=19 nM). |
|
| DC12629 | CM-675 | CM-675 (CM675) is a potent, dual PDE5 and classI-HDAC inhibitor with IC50 of 114/673 nM for PDE5A/HDAC1, respectively. |
|
| DC20913 | CMA-008 | CMA-008 is a cell-permeable, small molecule modulator of NAADP-mediated Ca2+ release, competes with NAADP binding, inhibit Ca2+ release via the NAADP receptor (IC50=15 uM-1 mM). |
|
| DC23813 | CMC2.24 | CMC2.24 (TRB-N0224) is a novel tricarbonylmethane agent that inhibits the Ras-RAF-MEK-ERK pathway, inhibits Ras activation in pancreatic cancer both in vitro and in vivo. |
|
| DC7388 | c-Met inhibitor 1 | c-Met inhibitor 1 is an inhibitor of the c-Met receptor signaling pathway useful for the treatment of cancer including gastric, glioblastoma, and pancreatic cancer. |
|
| DC9617 | CMK | CMK is a RSK2 kinase inhibitor. |
|
| DC21530 | CMP-5 Featured | CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells. |
|
| DC21531 | CMP-5 hydrochloride | CMP-5 (PRMT5-IN-5)is a first-in-class, small-molecule PRMT5-specific inhibitor that blocks EBV-driven B-lymphocyte transformation and survival, without effect on normal B cells. |
|
| DC23508 | CMPD167 | CMPD167 (MRK-1) is an orally acitve small molecule that binds to CCR5 to inhibit gp120 association, inhibits different stages of the virus-cell attachment and entry process (CCR5-using virus SHIV-162P3, IC50<1 nM).. |
|
| DC22512 | CMPDA Featured | CMPDA is a potent positive allosteric modulator of GluR2 receptors with EC50 of 45.4 and 63.4 nM at GluR2i and GluR2o respectively, in a calcium influx screening assays. |
|
| DC12477 | CN750 | CN750 (CN-750) is novel BRD4 (BD1, 2) inhibitor with IC50 of 44 nM, MV4-11 IC50 of 0.54 uM. |
|
| DC9370 | CNP-AFU | CNP-AFU (2-Chloro-4-nitrophenyl α-L-fucopyranoside) is a substrate for alpha-L-fucosidase(AFU). |
|
| DC7009 | CNS-7056 | CNS 7056 is a new short-acting sedative/anaesthetic that acts on GABAA receptors in the brain. |
|
| DC20346 | CN-SAH | CN-SAH is a potent and selective inhibitor of histone methyl transferase DOT1L with IC50 of 26 nM, displays >10-fold selectivity over DNMT1, PRMT3, PRMT5, and G9α.. |
|
| DC12103 | CNT2 inhibitor-1 | CNT2 inhibitor-1 is a potent concentrative nucleoside transporter 2 Inhibitor (CNT2), with an IC50 of 640 nM for hCNT2. |
|
| DC23180 | CNV1014802(Raxatrigine) Featured | CNV1014802 (GSK-1014802, Raxatrigine, Vixotrigine, BIIB074) is a potent, selective Nav1.7 sodium channel blocker, shows analgesic effects and potential in the treatment of cognitive symptoms of schizophrenia in vivo. |
|
| DC7104 | CNX-1351 | CNX-1351 is a selective covalent Inhibitor of PI3Kα. CNX-1351 was tested against all four of the class I PI3K enzymes α, β, γ, and δ. |
|
| DC7105 | CNX-2006 Featured | CNX-2006 is a novel irreversible mutant-selective EGFR inhibitor with IC50 of < 20 nM, with very weak inhibition at wild-type EGFR. |
|
| DC24119 | Cobimetinib racemate | Cobimetinib racemate is the racemate form of Cobimetinib (GDC-0973, XL518), which is a potent, highly selective inhibitor of MEK1/2.. |
|
| DC22505 | Cobimetinib R-enantiomer | Cobimetinib R-enantiomer (GDC-0973. |
|
| DC11081 | Coblopasvir | Coblopasvir (KW136, KW-136) is a novel HCV NS5A inhibitor under development for treatment of HCV infection.. |
|
| DC10430 | COH29 | COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity with an IC50 of 8 μM in KB cell. |
|
| DC22149 | COH-SR4 | COH-SR4 (Mitochondria uncoupler SR4) is a bonafide uncoupler that induces energetic stress on cells, consequently leading to AMPK activation and mTOR inhibition without any effects on ERK/MEK MAPK signaling. |
|
| DC23785 | Col 003 | Col 003 is a small-molecule compound that inhibits the interaction of Hsp47 with collagen with IC50 of 1.8 uM, binds to the collagen-binding site on Hsp47. |
|
| DC7813 | Collagen proline hydroxylase inhibitor | Collagen proline hydroxylase inhibitor is a collagen proline hydroxylase inhibitor; useful for antifibroproliferative agents. |
|
| DC7608 | OXi-4503 | Combretastatin A1 diphosphate OXi4503 is the diphosphate prodrug of the stilbenoid combretastatin A1, originally isolated from the plant Combretum caffrum, with vascular-disrupting and antineoplastic activities. |
|
